Recruitment of First Patient in Clinical Study
News Mar 30, 2016
Lamellar Biomedical and the Beatson West of Scotland Cancer Centre have announced the recruitment of the first subject in their clinical study assessing Visco-ease’s ability to restore the function of saliva in patients undergoing radiotherapy for the treatment of Head and Neck Cancer. RIX is a significant clinical problem for which there is no effective current treatment.
The trial is a double blind, randomised, placebo controlled, single centre, parallel group study. Patients will be randomised to receive Visco-ease or placebo, both of which will be delivered via a spray device specially developed for use in the oncology setting. The study expects to recruit 35 patients. The primary end-point of the study is to quantify the effectiveness of Visco-ease when compared to placebo in ameliorating dry mouth as assessed by the Groningen Radiotherapy-Induced Xerostomia questionnaire (GRIX).
The secondary endpoints of the study focus on the safety of Visco-ease. The results of the study are expected to be reported in H2 2016. The study is sponsored by the Greater Glasgow and Clyde Health Board as part of NHS Scotland. An ex vivo study, also conducted at the Beatson, which was published in the journal of Supportive Care in Cancer, showed that Visco-ease was able to restore the functional properties of RIX saliva taken from patients undergoing radiotherapy for Head and Neck Cancer.
Chief Investigator, Dr Claire Paterson of the Beatson, said: “We are extremely pleased and excited to start this study. There is a clear need for a new effective treatment for RIX, which has a very significant impact on the health and quality of life of patients undergoing radiotherapy. The positive results we achieved with Visco-ease in the ex vivo study we undertook last year, makes us hopeful that this novel product could be a major breakthrough in the treatment of RIX, something that we and other cancer centres around the world have been looking for.”
Alec McLean, the CEO of Lamellar Biomedical, said: “We would like to take this opportunity of thanking the Beatson Cancer Centre and NHS Scotland for their encouragement and support in starting our first ever clinical study with Visco-ease. I am looking forward to the results of the study as we develop Visco?ease as an important advance in the treatment of RIX paving the way for its commercial launch in 2016. The results of this clinical trial are expected to lead to Visco-ease gaining CE Mark approval in the second half of 2016, allowing the product to be commercialised in Europe”.
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.
Insulin Goes Viral: Diabetes and Cancer-causing Mechanisms ExploredNews
Every cell in your body responds to the hormone insulin, and if that process starts to fail, you get diabetes. In an unexpected finding, scientists have identified four viruses that can produce insulin-like hormones that are active on human cells. The discovery brings new possibilities for revealing biological mechanisms that may cause diabetes or cancer.READ MORE
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018